These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24646118)

  • 21. Large-scale High-throughput Screening Revealed 5'-(carbonylamino)-2,3'- bithiophene-4'-carboxylate as Novel Template for Antibacterial Agents.
    Ivanenkov YA; Yamidanov RS; Osterman IA; Sergiev PV; Aladinskiy VA; Aladinskaya AV; Terentiev VA; Veselov MS; Ayginin AA; Skvortsov DA; Komarova KS; Zagribelnyy BA; Baimiev AK; Shvetc KY; Baimiev AK; Sofronova AA; Machulkin AE; Petrov RA; Zainullina LF; Maximova MA; Zileeva ZR; Vakhitova YV; Bezrukov DS; Puchinina MM; Dontsova OA
    Curr Drug Discov Technol; 2020; 17(5):716-724. PubMed ID: 31161993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges and shortcomings of antibacterial discovery projects.
    Theuretzbacher U; Baraldi E; Ciabuschi F; Callegari S
    Clin Microbiol Infect; 2023 May; 29(5):610-615. PubMed ID: 36503116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Keeping it simple: lessons from the golden era of antibiotic discovery.
    Lyddiard D; Jones GL; Greatrex BW
    FEMS Microbiol Lett; 2016 Apr; 363(8):. PubMed ID: 27036144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
    Brogan DM; Mossialos E
    Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Antibacterial Compounds and their Drug Targets - Successes and Challenges.
    Kaczor AA; Polski A; Sobótka-Polska K; Pachuta-Stec A; Makarska-Bialokoz M; Pitucha M
    Curr Med Chem; 2017; 24(18):1948-1982. PubMed ID: 27978802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thinking Outside the Box-Novel Antibacterials To Tackle the Resistance Crisis.
    Lakemeyer M; Zhao W; Mandl FA; Hammann P; Sieber SA
    Angew Chem Int Ed Engl; 2018 Oct; 57(44):14440-14475. PubMed ID: 29939462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fighting antibiotic resistance-strategies and (pre)clinical developments to find new antibacterials.
    Walesch S; Birkelbach J; Jézéquel G; Haeckl FPJ; Hegemann JD; Hesterkamp T; Hirsch AKH; Hammann P; Müller R
    EMBO Rep; 2023 Jan; 24(1):e56033. PubMed ID: 36533629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-based discovery of antibacterial drugs.
    Simmons KJ; Chopra I; Fishwick CW
    Nat Rev Microbiol; 2010 Jul; 8(7):501-10. PubMed ID: 20551974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
    Simpkin VL; Renwick MJ; Kelly R; Mossialos E
    J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unconventional Antibacterials and Adjuvants.
    Chang M; Mahasenan KV; Hermoso JA; Mobashery S
    Acc Chem Res; 2021 Feb; 54(4):917-929. PubMed ID: 33512995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small and lethal: searching for new antibacterial compounds with novel modes of action.
    Pathania R; Brown ED
    Biochem Cell Biol; 2008 Apr; 86(2):111-5. PubMed ID: 18443624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current challenges in the discovery of novel antibacterials from microbial natural products.
    Genilloud O
    Recent Pat Antiinfect Drug Discov; 2012 Dec; 7(3):189-204. PubMed ID: 22963258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Future antibiotics scenarios: is the tide starting to turn?
    Theuretzbacher U
    Int J Antimicrob Agents; 2009 Jul; 34(1):15-20. PubMed ID: 19342202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using the Bacterial Ribosome as a Discovery Platform for Peptide-Based Antibiotics.
    Charon J; Manteca A; Innis CA
    Biochemistry; 2019 Jan; 58(2):75-84. PubMed ID: 30372045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A New Product Development Partnership Model for Antibiotic Resistance.
    Billington JK
    Am J Law Med; 2016 May; 42(2-3):487-523. PubMed ID: 29086636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The antibiotic resistome: challenge and opportunity for therapeutic intervention.
    Martínez JL
    Future Med Chem; 2012 Mar; 4(3):347-59. PubMed ID: 22393941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applications of structure-based design to antibacterial drug discovery.
    Cain R; Narramore S; McPhillie M; Simmons K; Fishwick CW
    Bioorg Chem; 2014 Aug; 55():69-76. PubMed ID: 24962384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore.
    Miller JR; Dunham S; Mochalkin I; Banotai C; Bowman M; Buist S; Dunkle B; Hanna D; Harwood HJ; Huband MD; Karnovsky A; Kuhn M; Limberakis C; Liu JY; Mehrens S; Mueller WT; Narasimhan L; Ogden A; Ohren J; Prasad JV; Shelly JA; Skerlos L; Sulavik M; Thomas VH; VanderRoest S; Wang L; Wang Z; Whitton A; Zhu T; Stover CK
    Proc Natl Acad Sci U S A; 2009 Feb; 106(6):1737-42. PubMed ID: 19164768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.